Have your medicines reached their full potential? Adare has the ability to solve complex formulation challenges and create or extend IP protection for new or existing medicines.
Have your medicines reached their full potential? Adare has the ability to solve complex formulation challenges and create or extend IP protection for new or existing medicines.
Taste Masking and ODTs
Several factors, such as bitter taste, administration difficulty, dosing frequency, and inconvenience, contribute to the lack of patient acceptance and adherence to a prescribed therapy. Microcaps®, AdvaTab®, and Liquitard® technologies address these complex formulation challenges by improving taste, promoting ease of administration, and adding convenience.
Customized Drug Release
To optimize the therapeutic performance of drugs, customized drug-release profiles can be combined to improve efficacy, enhance safety, and reduce dosing frequency.
Diffucaps®, Diffutab®, Eurand Minitabs®, and Orbexa™ proprietary technologies can create novel customized-release profiles that optimize the therapeutic performance of pharmaceutical products.
Bioavailability Enhancement
The bioavailability of a drug is strongly dependent on its solubility in the aqueous environment of the GI tract.
Biorise™ and Diffucaps® (Solid-Solution or Solid-Dispersion) enhance bioavailability of drugs that are poorly soluble at physiological pH levels.
With these proprietary technologies, Adare can help you add further value to your products, while meeting patients’ unique needs. To learn more about our proprietary technologies or partnership opportunities, contact Lisa.Miller@adarepharma.com or visit www.AdarePharma.com.
©2015 Adare Pharmaceuticals, Inc.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.